Sage Therapeutics, Inc.

NasdaqGM:SAGE Stock Report

Market Cap: US$443.5m

Sage Therapeutics Management

Management criteria checks 1/4

Sage Therapeutics' CEO is Barry Greene, appointed in Dec 2020, has a tenure of 4.17 years. total yearly compensation is $6.24M, comprised of 12.8% salary and 87.2% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $616.74K. The average tenure of the management team and the board of directors is 1.5 years and 9.5 years respectively.

Key information

Barry Greene

Chief executive officer

US$6.2m

Total compensation

CEO salary percentage12.8%
CEO tenure4.2yrs
CEO ownership0.1%
Management average tenure1.5yrs
Board average tenure9.5yrs

Recent management updates

Recent updates

Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae's Potential And Biogen's Bid

Jan 22

Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders

Jan 15

CNS Drug Development: Same As It Ever Was

Nov 19

Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left

Oct 07

Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge

Aug 30
Why Investors Shouldn't Be Surprised By Sage Therapeutics, Inc.'s (NASDAQ:SAGE) 25% Share Price Plunge

Sage Therapeutics: Tremors Of Trouble, But PPD Progress (Rating Downgrade)

Jul 25

Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price

Jul 13
Revenues Working Against Sage Therapeutics, Inc.'s (NASDAQ:SAGE) Share Price

Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

May 30

Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

May 21
Is Sage Therapeutics (NASDAQ:SAGE) In A Good Position To Invest In Growth?

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Feb 22
Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Feb 15
Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Sizing Up Sage Therapeutics

Jan 22

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Aug 09
Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Feb 22
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Nov 12
An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Oct 14
Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Aug 02

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Jun 15
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics: Well-Funded But Uninspiring Data

Mar 24

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Feb 26
We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics: Biogen's Backing May See It Through

Jan 04

CEO Compensation Analysis

How has Barry Greene's remuneration changed compared to Sage Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$338m

Jun 30 2024n/an/a

-US$446m

Mar 31 2024n/an/a

-US$503m

Dec 31 2023US$6mUS$799k

-US$541m

Sep 30 2023n/an/a

-US$656m

Jun 30 2023n/an/a

-US$592m

Mar 31 2023n/an/a

-US$558m

Dec 31 2022US$6mUS$761k

-US$533m

Sep 30 2022n/an/a

-US$510m

Jun 30 2022n/an/a

-US$503m

Mar 31 2022n/an/a

-US$484m

Dec 31 2021US$59mUS$735k

-US$458m

Sep 30 2021n/an/a

US$642m

Jun 30 2021n/an/a

US$666m

Mar 31 2021n/an/a

US$637m

Dec 31 2020US$836kUS$53k

US$606m

Compensation vs Market: Barry's total compensation ($USD6.24M) is above average for companies of similar size in the US market ($USD2.16M).

Compensation vs Earnings: Barry's compensation has increased whilst the company is unprofitable.

CEO

Barry Greene (61 yo)

4.2yrs

Tenure

US$6,237,491

Compensation

Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020 and its Director since October 1, 2020. Mr. Greene joined the Sage Therapeutics, Inc....

Leadership Team

NamePositionTenureCompensationOwnership
Barry Greene
President4.2yrsUS$6.24m0.14%
$ 616.7k
Christopher Benecchi
Chief Operating Officerless than a yearUS$2.28m0.0081%
$ 36.1k
Laura Gault
Chief Medical Officer2.3yrsUS$1.27m0.019%
$ 82.2k
Mike Quirk
Chief Scientific Officer1.5yrsno datano data
Ashley Kaplowitz
Director of Investor Relationsno datano datano data
Gregory Shiferman
Senior VP & General Counselless than a yearno datano data
Pamela Herbster
VP & Head of Peopleless than a yearno datano data
Helen Colquhoun
Senior Vice President of Drug Safety & Pharmacovigilanceno datano datano data
Vanessa Procter
Senior Vice President of Corporate Affairs3.3yrsno datano data
Aaron Koenig
Medical Director of Early Clinical Developmentno datano datano data
Maren Killackey
Senior Analyst of Investor Relationno datano datano data
Jeff Boyle
Investor Contactno datano datano data

1.5yrs

Average Tenure

55yo

Average Age

Experienced Management: SAGE's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Barry Greene
President4.3yrsUS$6.24m0.14%
$ 616.7k
Michael Cola
Independent Director10.4yrsUS$440.05k0%
$ 0
James Frates
Independent Director10.8yrsUS$435.05k0.0046%
$ 20.6k
David Farb
Member of Scientific Advisory Boardno datano datano data
Geno Germano
Independent Chair of the Board8.6yrsUS$417.55k0%
$ 0
Michael Rogawski
Member of Scientific Advisory Boardno datano datano data
James Audia
Member of Scientific Advisory Boardno datano datano data
Christine Marx
Member of Scientific Advisory Boardno datano datano data
A. Morrow
Member of Scientific Advisory Boardno datano datano data
Stephen Moss
Member of Scientific Advisory Boardno datano datano data
Scott Runyon
Member of Scientific Advisory Boardno datano datano data
Donald Stein
Member of Scientific Advisory Boardno datano datano data

9.5yrs

Average Tenure

63yo

Average Age

Experienced Board: SAGE's board of directors are considered experienced (9.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 02:53
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sage Therapeutics, Inc. is covered by 39 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Esther Lannie HongBerenberg
Gary NachmanBMO Capital Markets Equity Research